CRISPR Therapeutics
CRSP
CRSP
434 hedge funds and large institutions have $3.28B invested in CRISPR Therapeutics in 2022 Q2 according to their latest regulatory filings, with 59 funds opening new positions, 124 increasing their positions, 122 reducing their positions, and 62 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more ownership
Funds ownership: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
5% less first-time investments, than exits
New positions opened: 59 | Existing positions closed: 62
2% less funds holding
Funds holding: 445 → 434 (-11)
5% less capital invested
Capital invested by funds: $3.47B → $3.28B (-$186M)
Holders
434
Holding in Top 10
5
Calls
$193M
Puts
$182M
Top Buyers
| 1 | +$112M | |
| 2 | +$66.4M | |
| 3 | +$64.5M | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$30.4M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$25.5M |
Top Sellers
| 1 | -$16.9M | |
| 2 | -$16.6M | |
| 3 | -$14M | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$12.6M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$12.4M |